Intech Investment Management LLC Invests $426,000 in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Intech Investment Management LLC acquired a new position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 10,658 shares of the company’s stock, valued at approximately $426,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Epoch Investment Partners Inc. increased its stake in shares of Amphastar Pharmaceuticals by 348.7% in the fourth quarter. Epoch Investment Partners Inc. now owns 592,530 shares of the company’s stock worth $36,648,000 after acquiring an additional 460,473 shares during the period. TD Asset Management Inc grew its position in Amphastar Pharmaceuticals by 449.0% during the fourth quarter. TD Asset Management Inc now owns 793,559 shares of the company’s stock valued at $49,082,000 after buying an additional 649,001 shares during the period. Silvercrest Asset Management Group LLC grew its position in Amphastar Pharmaceuticals by 35.1% during the first quarter. Silvercrest Asset Management Group LLC now owns 112,428 shares of the company’s stock valued at $4,937,000 after buying an additional 29,182 shares during the period. US Bancorp DE grew its position in Amphastar Pharmaceuticals by 2,648.8% during the fourth quarter. US Bancorp DE now owns 21,248 shares of the company’s stock valued at $1,314,000 after buying an additional 20,475 shares during the period. Finally, Allspring Global Investments Holdings LLC grew its position in Amphastar Pharmaceuticals by 61.9% during the first quarter. Allspring Global Investments Holdings LLC now owns 64,564 shares of the company’s stock valued at $2,835,000 after buying an additional 24,678 shares during the period. Institutional investors and hedge funds own 65.09% of the company’s stock.

Insider Transactions at Amphastar Pharmaceuticals

In other news, Director Floyd F. Petersen sold 3,000 shares of the firm’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $46.47, for a total value of $139,410.00. Following the transaction, the director now directly owns 75,409 shares of the company’s stock, valued at $3,504,256.23. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Amphastar Pharmaceuticals news, EVP Rong Zhou sold 4,000 shares of Amphastar Pharmaceuticals stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $48.35, for a total transaction of $193,400.00. Following the transaction, the executive vice president now directly owns 118,388 shares of the company’s stock, valued at $5,724,059.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Floyd F. Petersen sold 3,000 shares of Amphastar Pharmaceuticals stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $46.47, for a total transaction of $139,410.00. Following the transaction, the director now directly owns 75,409 shares in the company, valued at $3,504,256.23. The disclosure for this sale can be found here. Over the last three months, insiders have sold 34,383 shares of company stock valued at $1,524,123. Corporate insiders own 27.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. StockNews.com upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, September 20th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Thursday, August 8th. Finally, Piper Sandler decreased their price objective on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $63.00.

Amphastar Pharmaceuticals Stock Performance

AMPH opened at $48.02 on Friday. The company has a quick ratio of 2.63, a current ratio of 3.52 and a debt-to-equity ratio of 0.82. The company has a market cap of $2.35 billion, a price-to-earnings ratio of 16.62, a PEG ratio of 0.92 and a beta of 0.82. Amphastar Pharmaceuticals, Inc. has a 52-week low of $36.56 and a 52-week high of $65.92. The firm’s fifty day simple moving average is $45.39 and its two-hundred day simple moving average is $42.73.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Wednesday, August 7th. The company reported $0.85 earnings per share for the quarter, topping the consensus estimate of $0.75 by $0.10. The firm had revenue of $182.39 million for the quarter, compared to the consensus estimate of $171.29 million. Amphastar Pharmaceuticals had a net margin of 23.36% and a return on equity of 29.79%. Equities analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 3.71 earnings per share for the current fiscal year.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.